Corporate

Jul, 2022

News / Corporate

Jul 04, 2022

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mogrify Limited (CEO: Darrin M. Disley, Ph.D., "Mogrify®"), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas...

Jun, 2022

News / Corporate

Jun 27, 2022

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer...

News / Corporate

May 31, 2022

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...

Apr, 2022

News / Corporate

Apr 25, 2022

Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovation in Cancer Care Beyond Medicine

- Addressing everyday challenges in cancer care; apply by June 3, 2022 - NORTHBROOK, Ill., April 25, 2022 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced that it is accepting...

News / Corporate

Apr 24, 2022

University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions

The University of Tokyo (President: Teruo Fujii, Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.; hereafter "Astellas") entered the second phase of their...